Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
CNY 15.06
(0.53%)
CNY 15.06
(0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.71 Billion CNY | 170.33% |
| 2022 | 1 Billion CNY | -56.74% |
| 2021 | 2.32 Billion CNY | 16.94% |
| 2020 | 1.98 Billion CNY | 123.29% |
| 2019 | 889 Million CNY | 59.39% |
| 2018 | 557.75 Million CNY | 252.76% |
| 2017 | -365.1 Million CNY | 90.39% |
| 2016 | -3.8 Billion CNY | -3534.47% |
| 2015 | 110.66 Million CNY | 125.55% |
| 2014 | -433.07 Million CNY | -24.1% |
| 2013 | -348.96 Million CNY | 72.65% |
| 2012 | -1.27 Billion CNY | -7.74% |
| 2011 | -1.18 Billion CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.88 Billion CNY | -1.81% |
| 2024 Q1 | 2.93 Billion CNY | 8.08% |
| 2024 Q3 | 2.06 Billion CNY | -28.09% |
| 2023 FY | 2.71 Billion CNY | 170.33% |
| 2023 Q1 | 1.4 Billion CNY | 39.45% |
| 2023 Q2 | 722.06 Million CNY | -48.44% |
| 2023 Q4 | 2.71 Billion CNY | 3.98% |
| 2023 Q3 | 2.61 Billion CNY | 261.58% |
| 2022 FY | 1 Billion CNY | -56.74% |
| 2022 Q3 | 1.57 Billion CNY | -1.06% |
| 2022 Q2 | 1.58 Billion CNY | -23.41% |
| 2022 Q4 | 1 Billion CNY | -36.13% |
| 2022 Q1 | 2.07 Billion CNY | -10.61% |
| 2021 Q3 | 2.53 Billion CNY | 28.06% |
| 2021 FY | 2.32 Billion CNY | 16.94% |
| 2021 Q2 | 1.97 Billion CNY | 8.76% |
| 2021 Q4 | 2.32 Billion CNY | -8.33% |
| 2021 Q1 | 1.81 Billion CNY | -8.41% |
| 2020 Q3 | 1.84 Billion CNY | 106.33% |
| 2020 Q4 | 1.98 Billion CNY | 7.84% |
| 2020 FY | 1.98 Billion CNY | 123.29% |
| 2020 Q1 | 1.41 Billion CNY | 59.14% |
| 2020 Q2 | 892.12 Million CNY | -36.94% |
| 2019 Q4 | 889 Million CNY | 55.66% |
| 2019 Q2 | 381.25 Million CNY | 26.34% |
| 2019 FY | 889 Million CNY | 59.39% |
| 2019 Q1 | 301.76 Million CNY | -45.9% |
| 2019 Q3 | 571.11 Million CNY | 49.8% |
| 2018 Q2 | -1.21 Billion CNY | -298.02% |
| 2018 FY | 557.75 Million CNY | 252.76% |
| 2018 Q4 | 557.75 Million CNY | 194.82% |
| 2018 Q3 | -588.25 Million CNY | 51.59% |
| 2018 Q1 | -305.29 Million CNY | 16.38% |
| 2017 FY | -365.1 Million CNY | 90.39% |
| 2017 Q1 | -604.53 Million CNY | 84.09% |
| 2017 Q2 | -1.11 Billion CNY | -85.16% |
| 2017 Q3 | -95.3 Million CNY | 91.49% |
| 2017 Q4 | -365.1 Million CNY | -283.08% |
| 2016 Q2 | 146.65 Million CNY | -92.08% |
| 2016 Q4 | -3.8 Billion CNY | -2011.6% |
| 2016 Q3 | -179.98 Million CNY | -222.73% |
| 2016 Q1 | 1.85 Billion CNY | 1572.98% |
| 2016 FY | -3.8 Billion CNY | -3534.47% |
| 2015 FY | 110.66 Million CNY | 125.55% |
| 2015 Q4 | 110.66 Million CNY | 0.0% |
| 2014 FY | -433.07 Million CNY | -24.1% |
| 2013 FY | -348.96 Million CNY | 72.65% |
| 2012 FY | -1.27 Billion CNY | -7.74% |
| 2011 FY | -1.18 Billion CNY | 0.0% |